The burgeoning landscape of therapy for obesity and type 2 glucose intolerance is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant differences in their pharmacological profiles and clinical investigation results are emerging. Retatruti

Retaglutide and tirzepatide represent a novel type of medications known as dual GLP-1 and GIP agonists. These agents influence both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that play a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones are of